Marketing of Formulation by Drug Companies

1506. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that a number of drug companies are marketing formulations without obtaining price approval after getting them manufactured from small scale units;

(b) the names of the products, its composition and price at which each is being marketed by Glaxo, Hoechst, Wockhardt, Fairdeal Corporation, Dolphin Laboratories and German Remedies alongwith name and address of each small scale unit from which each product is being got manufactured;

(c) whether his Ministry has fixed prices of other brands having same composition;

(d) if so, what are the names of the products and prices fixed for each;

(e) since when such practice is going on and by when this will be stopped; and

(f) what is the sales turnover of each such product during the last three years, yearwise and how much per year consumer is paying in excess to each company?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICANDRA SINGH): (a) to (f) Instances of large and medium scale drug units marketing their products after getting them manufactured by small scale units who are exempted from seeking price approval for category III products under Drugs Prices Control Order, 1979 have come to the notice of the Government. Such units are free to make marketing arrangements with other units under the law. This aspect will be kept in view while issuing new Drug Prices Control Order on the basis of the measures announced by the Government in December, 1986. Sales turnover of the formulations is not monitored.

Challenging the Government Fixed Prices by Drug Companies

1507. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Glaxo, Cyanamid, Hoechst, Pfizer and Merind Challenged the prices fixed by his Ministry in various Courts;

(b) if so, names of builk drugs and formulations against which petitions were filed alongwith the price fixed of each and price being charged by each company of each drug and formulation;

(c) whether his Ministry worked out the prices of each formulation based on each bulk drug of each company on the basis of Government fixed price;

(d) if so, the price worked out of each under DPCO, 1979;

(e) what is the difference on each price fixed and price charged and since when each of the company is selling at their existing prices;

(f) whether it is a fact that the Supreme Court has observed such activities as menace which needs to be curbed immediately; and

(g) if so, what steps are proposed to be taken by his Ministry?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) to (e) To the extent information is available, names of bulk drugs and formulations prices of which were challenged are given in the attached Statement (*See* below). Rest of the details

will be collected and laid on the Table of the Rajya Sabha.

(f) and (g) The Supreme Court in its judgement on 10th April, 1987 has observed that profiteering in life saving drugs is diabolic and is a menace which has to be fettered and curbed. The judgement is being examined.

Statement

Sl. No.	Name of the company	Name of the bulk drug/formulation
1	M/s. Glaxo Labs. I. Ltd.	Betamethasone and its formulations.
2	M/s Cynamid India Ltd.	Tetracyclines & formaulations and Diethyl Carbamazine formulations.
3	M/s. Hoechst India Ltd	Baralgan, Pyrolidine Methyl Tetracycline, Pheniramine, Glybenclamide Frusemid and formulations.
4	M/s. Pfizer Ltd.	Oxytetracycline, PAS and its salts and formulations based thereon.
5	M/s. Merind Ltd.	Dexamethasone and its formulations.

Marketing of essential medicines by drug companies

1508. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRRY be pleased to state:

(a) whether it is a fact that certain companies were found marketing certain essential medicines falling under Category I and II under other categories;

(b) if so, what are the names of those companies alongwith the name of each product;

(c) whether his Ministry has worked out the prices of those medicines as per correct mark up;

(d) if so, what is the price worked out and price being charged on each product alongwith percentage increase in each case;

(e) whether his Ministry issued a claim of difference;

(f) if so, what is the amount of claim on each product;

(g) whether his Ministry has worked out interest on that amount;

(h) if so, at what rate and if not, what are the reasons therefor;

(i) whether his Ministry has taken any penal action against those drug companies; and

(j) if so, what are the details thereof and if not, what are the reasons therefor?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRAR SINGH): (a) No, Sir.

(b) to (j) Do not arise.

Multinational bias of New Drug Policy

1509. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the convention of the various sections of drug industry have considered the New Drug Policy as multinational oriented; and